focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Woodford offloading 7pc to Jupiter. Jupiter must see some value in it. Bodes well for a re-listing.
Hemo growth is +6k tests H1-18 vs H2-17 = c. 22%. NOT 10%
Cr*p
Teslin P have picked up another 2pc. Their stake building has been ignored by the market. They have a strong track record of backing businesses at the point of transformation. I�m going to follow their lead and pick up another 10k or so.
The New UK Claim from Illumina and Sequenom (the "Claimants") was filed in September 2017 and alleges that Premaitha's IONA� test infringes European Patent (UK) 1 524 321 82, known as the "321" patent, as filed by Sequenom in 2003 and as included in a Pooled Patents Agreement (PPA) entered into between Sequenom and Illumina in late 2014. The Claimants have also asserted the patent against other competitors, Ariosa and The Doctors Laboratory ("Ariosa/TDL") (together with Premaitha, the "Defendants"). At a hearing held in the High Court on 16 March 2018, the judge heard applications made by the Defendants, that the New UK Claim was an abuse of the legal process and should be struck out. The Defendants argued that the abuse arose, in part, because the New UK Claim could and should have been brought much earlier by the Claimants, and that this had caused prejudice to the Defendants. No questions of patent validity or alleged infringement were addressed in the proceedings. In assessing abuse of process claims the courts take a broad, merits‑based approach. After considering all the facts in the case the judge determined that, whilst Illumina and Sequenom ought to have known in 2015 whether they had a claim against the Defendants or not, there was no evidence that they did know and nor that they had deliberately delayed bringing the New UK Claim. The judge also stated that any additional costs incurred by the Defendants as a result of the later filing of the New UK Claim could be redressed at the end of the usual legal process. As a result, the judge denied the applications from the Defendants to strike out the New UK Claim. The written ruling was made public on 23 March 2018, and at a final order hearing on the same day the judge awarded costs of approximately �50,000 against Premaitha (and also costs against Ariosa/TDL). The New UK Claim will therefore proceed on a normal timetable and is expected to come to trial in early 2019. Dr Stephen Little, CEO of Premaitha Health, commented: "We made this application in an attempt to minimise any UK business disruption from the New UK Claim. We are disappointed the judge did not agree with our arguments and those of the other parties as to why we feel the claim is an abuse of process, but we remain firmly of the view that the claim itself can be defended effectively. Unfortunately, the UK market remains a challenging legal environment for ourselves and other competitors. Ultimately, the consequence of these various sets of proceedings may restrict the choice of NIPT for British women. We are currently reviewing our options in the UK with new legal advisers and we will update investors on the next steps alongside our year end trading update which is expected in April. "Over the last three years, and from a standing start, Premaitha has built a significant global business, yet has been hindered in its domestic market
why the drop this morning. anyone know?
Profit warning just issued....profits gonna be half of what management projected just 3 months ago. Ouch!